(Q37925811)

English

Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders

scientific article published on October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

0 references

1 reference

Europe PubMed Central

Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

0 references

1 reference

based on heuristic

inferred from title

Salvatore Gentile

1

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Pediatric Drugs

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

291-302

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

https://scigraph.springernature.com/pub.10.2165/11591250-000000000-00000

0 references

Child and adolescent schizophrenia: pharmacological approaches

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Children with schizophrenia: clinical picture and pharmacological treatment.

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

The relationship between duration of untreated psychosis and outcome: an eight-year prospective study.

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Outcome of a first episode of psychosis in adolescence: a 2-year follow-up

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Preschool bipolar disorder.

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Pediatric bipolar disorder: validity, phenomenology, and recommendations for diagnosis

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

National trends in the outpatient diagnosis and treatment of bipolar disorder in youth

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Phenomenology of children and adolescents with bipolar spectrum disorders

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Pharmacologic treatment of pediatric bipolar disorder

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Pharmacotherapy of bipolar disorder in children and adolescents: recent progress

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Olanzapine versus placebo in the treatment of adolescents with bipolar mania

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Clinical trials in children.

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Assessment of risk of bias among pediatric randomized controlled trials

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Olanzapine in male and female adolescent patients with schizophrenia and related disorders: minor sex differences in outcomes

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Combination pharmacotherapy in children and adolescents with bipolar disorder

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Treatment guidelines for children and adolescents with bipolar disorder

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Prevalence of overweight and obesity in adolescents with severe mental illness: a cross-sectional chart review

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Metabolic screening in children receiving antipsychotic drug treatment

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry

1 reference

https://api.crossref.org/works/10.2165%2F11591250-000000000-00000

21 January 2018

Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology of Schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology of early-onset schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic orphans

1 reference

https://pubmed.ncbi.nlm.nih.gov/21888443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11591250-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37925811&oldid=1733745063"